Skip to main content
. 2022 Mar 16;10(2):e01814-21. doi: 10.1128/spectrum.01814-21

FIG 6.

FIG 6

Neutralization of SARS-CoV-2 Alpha, Gamma, Delta, and Epsilon variants by mAbs S2-4D, S2-5D, and S2-8D. (A) The mAbs S2-4D, S2-5D, S2-8D (60 μg/mL), and a neutralizing chimeric antibody RBD-chAb-45 (100 ng/mL) against the RBD of SARS-CoV-2 S protein were preincubated with SARS-CoV-2 wild type (white bars), Alpha (gray bars), Epsilon (blue bars), Delta (yellow bars), and Gamma (black bars) variants and then subjected to the plaque reduction assay. Five to 7 days later, plaques were counted and the inhibition of the plaque formation was calculated by comparing to the experimental results in the absence of antibodies. Data are presented as means ± SD of three biological replicates (n =3). One-way ANOVA was used for statistical analysis. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. (B) The EC50 values of S2-4D, S2-5D, S2-8D, and RBD-chAb-45 against different SARS-CoV-2 variants.